3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
17
Colonic Neoplasms
7
Rectal Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Pancreatic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Unresectable Metastatic Colorectal Cancer
2
Ovarian Neoplasms
2
Gastrointestinal Neoplasms
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumors
1
Prostatic Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Locally-advanced Rectal Cancer
1
Gastroesophageal Adenocarcinoma
1
Endometrial Neoplasms
1
Colorectal Cancer Metastatic
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
47
Nivolumab
34
Sunitinib
18
Cyclophosphamide
18
Everolimus
17
Ipilimumab
15
cabozantinib
14
pazopanib
13
Bevacizumab
13
fludarabine
12
atezolizumab
11
temsirolimus
10
Magnetic Resonance Spectroscopy
10
Sorafenib
9
aldesleukin
8
Specimen Handling
8
Paclitaxel
8
Sirolimus
7
CTLA-4 Antigen
7
Axitinib
7
belzutifan
6
Radiosurgery
6
Oxaliplatin
6
Interleukin-2
6
Fluorouracil
6
spartalizumab
5
avelumab
5
Leucovorin
5
Irinotecan
5
Docetaxel
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Carcinoma, Renal Cell
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled